Allergan Inc. (AGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Allergan fell $1.04 (-1.2%) to $87.75 on average volume. Throughout the day, 3,407,462 shares of Allergan exchanged hands as compared to its average daily volume of 2,534,500 shares. The stock ranged in price between $86.95-$88.56 after having opened the day at $88.18 as compared to the previous trading day's close of $88.79. Other companies within the Drugs industry that declined today were: NanoString Technologies ( NSTG), down 15.4%, AVANIR Pharmaceuticals ( AVNR), down 13.4%, Idenix Pharmaceuticals ( IDIX), down 7.9% and ProPhase Labs ( PRPH), down 7.0%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $26.4 billion and is part of the health care sector. Shares are down 3.2% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 47.7%, Aoxing Pharmaceutical Company ( AXN), up 31.8%, Galectin Therapeutics ( GALT), up 26.6% and GTx ( GTXI), up 21.4% , were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%